Abstract:Recent longitudinal PET imaging studies have established methods to estimate the age at which amyloid becomes abnormal at the level of the individual. Here we recontextualized amyloid levels into the temporal domain to better understand the downstream Alzheimer's disease processes of tau neurofibrillary tangle (NFT) accumulation and cognitive decline. This cohort study included a total of 601 individuals from the Wisconsin Registry for Alzheimer's Prevention and Wisconsin Alzheimer's Disease Research Center that underwent amyloid and tau PET, longitudinal neuropsychological assessments, and met clinical criteria for three clinical diagnosis groups: cognitively unimpaired (CU; n =537); mild cognitive impairment (MCI; n =48); or dementia ( n =16)). Cortical 11 C-Pittsburgh compound B (PiB) distribution volume ratio (DVR) and sampled iterative local approximation were used to estimate amyloid positive (A+; global PiB DVR>1.16 equivalent to 17.1 Centiloids) onset age and years of A+ duration at tau PET (i.e., amyloid chronicity). Tau PET burden was quantified using 18 F-MK-6240 standardized uptake value ratios (SUVRs; 70-90 min, inferior cerebellar gray matter reference region). Whole-brain and region-specific approaches were used to examine tau PET binding along the amyloid timeline and across the Alzheimer's disease clinical continuum. Voxel-wise 18 F-MK-6240 analyses revealed that with each decade of A+, the spatial extent of measurable tau spread (i.e., progressed) from regions associated with early to late NFT tau stages. Regional analyses indicated that tau burden in the entorhinal cortex was detectable, on average, within ten years of A+ onset. Additionally, the entorhinal cortex was the region most sensitive to early amyloid pathology and clinical impairment in this predominantly preclinical sample. Among initially CU ( n =472) individuals with longitudinal cognitive follow-up, mixed effects models showed significant linear and non-linear interactions of A+ duration and entorhinal tau on cognitive decline, suggesting a synergistic effect whereby greater A+ duration together with a higher entorhinal tau burden increases the likelihood of cognitive decline beyond their separable effects. Overall, the amyloid time framework enabled a spatiotemporal characterization of tau deposition patterns across the Alzheimer's disease continuum. This approach, which examined cross-sectional tau PET data along the amyloid timeline to make longitudinal disease-course inferences, demonstrated that A+ duration explains a considerable amount of variability in the magnitude and topography of tau spread, which largely recapitulated NFT staging observed in human neuropathological studies. By anchoring disease progression to the onset of amyloid, this study provides a temporal disease context which may help inform disease prognosis and timing windows for anti-amyloid therapies.

Tau-PET abnormality change along with Alzheimer’s disease: a topological perspective

Tau-PET abnormality as a biomarker for Alzheimer's disease staging and early detection: a topological perspective

Individualized Network Analysis: A Novel Approach to Investigate Tau PET Using Graph Theory in the Alzheimer's Disease Continuum.

Differences in Topography of Individual Amyloid Brain Networks by Amyloid PET Images in Healthy Control, Mild Cognitive Impairment, and Alzheimer's Disease

Study on tau brain network and asymmetry of Alzheimer′s disease based on 18F-APN-1607 PET imaging

Gray matter structural covariance networks changes along the Alzheimer's disease continuum.

INDIVIDUAL-BASED NETWORK ANALYSIS: A NOVEL APPROACH TO INVESTIGATE THE PATHOLOGICAL SPREAD OF PHF TAU USING GRAPH THEORY IN CLINICAL AND PRECLINICAL STAGES OF ALZHEIMER’S DISEASE

Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease

Topographic metabolism‐function relationships in Alzheimer's disease: A simultaneous PET/MRI study

Study on tau related disease pattern of Alzheimer′s disease based on 18F-APN-1607 PET imaging

Identification of Alzheimer's Disease Progression Stages Using Topological Measures of Resting-State Functional Connectivity Networks: A Comparative Study

Elevated Tau PET Signal Depends on Abnormal Amyloid Levels and Correlates with Cognitive Impairment in Elderly Persons without Dementia

Neurometabolic topography and associations with cognition in Alzheimer's disease: A whole-brain high-resolution 3D MRSI study

Altered Topological Properties of Functional Brain Network Associated with Alzheimer's Disease

Based on Tau PET Radiomics Analysis for the Classification of Alzheimer’s Disease and Mild Cognitive Impairment

Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease

A Novel Longitudinal Approach in Individual Subjects to Investigate the Movement of Tau over Time Using Graph Theory in Clinical and Preclinical Stages of Alzheimer’s Disease

The Imaging Features and Clinical Associations of a Novel Tau PET Tracer—18F-APN1607 in Alzheimer Disease

One-Year Longitudinal Changes in Tau Accumulation on [18F]PI-2620 PET in the Alzheimer Spectrum

White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease

An Unsupervised Region of Interest Extraction Model for Tau PET Images and Its Application in the Diagnosis of Alzheimer's Disease.